Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:2/6/2019
Start Date:September 2016
End Date:September 2026

Use our guide to learn which trials are right for you!

COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Test Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants With Potential Germline Mutations Identified on Tumor Profiling

This research trial studies how well pre-test genetic education and remote genetic counseling
works in communicating tumor profiling results to patients with advanced cancer. Web-based
genetic education before receiving tumor profiling results and remote genetic counseling for
patients with potential germline mutations may increase genetic knowledge and reduce distress
for patients with advanced cancer.

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of web-based pre-test genetic education (i.e. before receipt of
tumor profile results) to increase knowledge (genetic knowledge and knowledge of test
benefits and limitations). (Step 1)

II. To evaluate the efficacy of web-based pre-test genetic education (i.e. before receipt of
tumor profile results) to decrease distress (anxiety, depression and cancer specific worry)
compared to usual care services in patients undergoing tumor profiling for advanced cancer.
(Step 1)

III. To evaluate the uptake of remote genetic counseling (Step 2)

IV. To evaluate the uptake of germline testing among advanced cancer patients with a
potential clinically significant incidental germline mutation identified through tumor
profiling in the Molecular Analysis for Therapy Choice (MATCH) trial. (Step 2)

SECONDARY OBJECTIVES:

I. To evaluate potential moderators suggested by the self-regulation theory of health
behavior (SRTHB) (e.g. test result, sociodemographic factors, health literacy, baseline
knowledge or distress) to changes in knowledge of genetic disease and test benefits and
limitations. (Step 1)

II. To evaluate potential moderators suggested by the SRTHB (e.g test result,
sociodemographic factors, health literacy, baseline knowledge or distress) to changes in
distress in patients undergoing tumor profiling for advanced cancer. (Step 1)

III. To evaluate factors associated with uptake of genetic counseling and germline testing.
(Step 2)

IV. To evaluate cognitive, affective and behavioral (communication to relatives) responses to
confirmatory germline testing in advanced cancer patients with potential clinically
significant incidental germline mutation identified in tumor profiling. (Step 2)

OUTLINE:

STEP I (PRIMARY INTERVENTION STUDY): Participants are randomized to 1 of 2 arms.

ARM A: Patients receive web-based genetic education consisting of general information about
testing tumors for genetic mutations.

ARM B: Patients receive standard genetic education consisting of conversations with the
treating physicians, interaction with and information from the clinical staff, and
information from usual resources about testing for genetic mutations.

STEP II (SECONDARY GENETIC COUNSELING SUBSTUDY):

Patients who meet the criteria for the remote counseling substudy will receive genetic
counseling over the telephone and undergo germline testing.

After completion of study treatment, patients are followed up periodically.

Inclusion Criteria:

- (STEP 1) - PRIMARY INTERVENTION STUDY (RANDOMIZED CONTROLLED TRIAL [RCT]):

- Patients must be registered to the first screening step (Step 0) for the National
Cancer Institute (NCI)-MATCH trial (EAY131)

- Patients must speak English and have an adequate ability to view a website (primary
intervention study)

- (STEP 2) - SECONDARY GENETIC COUNSELING SUBSTUDY:

- Patients must have a potential germline mutation, as determined by the NCI-MATCH tumor
profiling assay

- Patients must be able to speak English and hear by phone
We found this trial at
1
site
Philadelphia, Pennsylvania 19103
Principal Investigator: Angela R. Bradbury
Phone: 215-615-3341
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials